Molecular analysis on resistant TB isolates in Portugal by Silva, Carla et al.
Session #1  P95
!
Molecular analysis on resistant TB isolates in Portugal
C. Silvaa, J. Perdiga˜ oa, L. Jorda˜ ob and I. Portugala
aCentro de Patoge´ nese Molecular, Av. Prof. Gama Pinto, 1649-003 Lisbon, Portugal; bInst. Nac. de 
Sau´ de, DDI, Av. Padre Cruz, 1649-016 Lisbon, Portugal
carlamsilva@ff.ul.pt
Portugal has one of the highest tuberculosis (TB) incidence (20/100 000 inhabitants) in Europe.  
The emergence of multidrug resistant (MDR) TB and extensive drug-resistant (XDR) TB 
infection is the biggest threat to TB control.  Most strains of MDR-TB circulating in the Lisbon 
area belong to a particular family of genetically related strains, the Lisboa family, detected in 
the 90’s. The prevalence of this family of strains has increased over the years, and represented 
more than 85% of the MDR-TB strains in the year of 2008. XDR-TB has been recently derived 
from MDR-TB strains and account for about 50% of these, the majority belonging to Lisboa 
family. Lisboa family represents a serious problem regarding TB control in Portugal and its 
prevalence in recent years suggests that these strains may have selective advantages over 
others. In order to establish a link between the most prevalent mutations in drug-resistance 
associated genes and spread of Lisboa strains in the Portuguese setting, 54 resistant-TB clinical 
isolates in Portugal were study. The isolates were characterized by 24 loci MIRU-VNTR and 
analyzed for inhA, katG, rpoB, rpsL, rrs, embB and pncA genes, for resistance to first-line drugs. 
The MDR isolates (n=35) were further analyzed for mutations in gyrA, tlyA, eis and rrs for 
resistance to fluoroquinolones and second-line injectables. MIRU-VNTR analysis showed that 
Lisboa family strains and Q1 cluster were the most prevalent, with 26 (48%) and 6 (11%) isolates 
respectively, including the majority of the MDR-TB and XDR- TB isolates. No mutations in first-line 
drug resistance associated genes specifically related with MDR were found. However, mutation 
analysis to second-line drug resistance in 17 MDR-TB isolates shown that specific mutations are 
present in particular families. Therefore, XDR-TB from Lisboa family exhibits gyrA D94G/S91P, 
tlyA Ins755GT and eis G-10A mutations, and XDR-TB from Q1 presents gyrA D94A and rrs 
A1401G mutations. The remaining isolates are still under study, and further analyses are ongoing. 
We conclude that XDR-TB isolates from Lisboa family and Q1 cluster have shown a marked 
difference between them, regarding second-line mutations. Such analysis may be useful to 
define mutation profiles that distinguish Lisboa family from Q1 isolates.
